Liberate Medical

Liberate Medical, founded in 2013 and headquartered in the United States, is a biotechnology and health care startup with the slogan "Helping Patients Take Their Next Breath." The company focuses on developing neuromuscular electrical stimulation technology to enhance the quality and reduce the cost of care for patients with pulmonary disorders. Liberate Medical's flagship product, the VentFree™ respiratory muscle stimulator, addresses a critical need in the medical field. It applies proprietary, non-invasive, electrical stimulation to the expiratory muscles in synchrony with exhalation while a patient is on mechanical ventilation. This breakthrough therapy aims to reduce abdominal muscle atrophy and the time taken to liberate patients from mechanical ventilation. The result is a potential reduction in days on mechanical ventilation, which could lead to decreased morbidity and mortality, improved quality of life, and substantial cost savings for the health care provider. The company recently secured a $6.20M Series B investment on 05 July 2023 from Scientific Health Development, demonstrating investor confidence in its innovative approach to respiratory care. With its focus on addressing a pressing healthcare challenge and the support from notable investors, Liberate Medical is poised to make a meaningful impact in the biotechnology and health care industries.